Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders.
Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.
Our Core Principles
Lysogene’s determination to advance scientific discovery and improve lives
is guided by core principles and values shared by our entire team.
Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen’s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers.
Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.
Together, we seek to transform lives by developing cutting-edge therapies for a broad range of genetic CNS diseases with high unmet need.